Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Código da empresaSTTK
Nome da EmpresaShattuck Labs Inc
Data de listagemOct 09, 2020
CEOSchreiber (Taylor)
Número de funcionários44
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 09
Endereço500 W. 5Th Street
CidadeAUSTIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal78701
Telefone15129004690
Sitehttps://www.shattucklabs.com/
Código da empresaSTTK
Data de listagemOct 09, 2020
CEOSchreiber (Taylor)
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados